Test Compendium is your definitive resource for detailed information on a wide array of diagnostic tests. Each entry in our compendium is meticulously cataloged to aid healthcare providers in selecting and interpreting the right tests for their patients.
Displaying 351 - 375 of 475
Concurrent DeepSight™ Comprehensive 523 genes Liquid Biopsy (Somatic) + Neovare Portfolio testing (Germline) Methodology Molecular Test Description Disease Solid tumors; Breast cancer, Ovarian cancer,
Concurrent DeepSight™ on Liquid + siPortfolio Multi-Omics™ on Tissue Methodology Molecular Test Description Disease Solid tumorsOn Tissue: siPortfolio Multi-Omics™ • NGS (500+ genes, TMB, MSI)
LymphoSight™ Test Description Probes/Genes IHC/CISH ALK1, BCL-1, BCL-2, BCL-6, BRAF, Bob1, CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD15, CD20, CD21, CD23, CD25*, CD30, CD43, CD79a, CD138, C-MYC, EBV-LMP, Granzyme B, ICOS*, IgA, IgG, IgG4, IgM, Kappa, Ki-67, Lambda, LEF1*, Mum1, OCT2, Pax5, Perforin, PD-1, TIA1. *: Pending CISH: EBER, Kappa,
D2-40 (Podoplanin) Methodology Immunohistochemistry (IHC) Test Description Probes/Genes D240 IHC Disease Confirmation of lymphovascular invasion, Primary skin adnexal tumors, Chondrosarcoma, Seminoma,
Desmin Methodology Immunohistochemistry (IHC) Test Description Probes/Genes DESMIN IHC Disease Identification of striated and smooth muscle cells and tumors52kDa cytoplasmic intermediate filament present
DOG-1 Methodology Immunohistochemistry (IHC) Test Description Probes/Genes DOG-1 IHC Disease Gastrointestinal stromal tumor (GIST)DOG-1, a 986 amino acid protein of unknown function, is expressed predominantly
E-Cadherin Methodology Immunohistochemistry (IHC) Test Description Probes/Genes ECADH IHC Disease Differentiation between lobular and ductal neoplasms of the breast, Diffuse type gastric adenocarcinoma,
EGFR and ALK-1 by IHC for NSCLC Methodology Immunohistochemistry (IHC) Test Description Probes/Genes EGFR IHC and ALK-1 IHC Disease Non-small cell lung cancersImmunohistochemistry has been proposed as
EMA Alternative Name Epithelial Membrane Antigen Methodology Immunohistochemistry (IHC) Test Description Probes/Genes EMA IHC Disease Meningioma, some hematopoietic tumors and malignant mesothelioma, and
Factor VIII (VW) Methodology Immunohistochemistry (IHC) Test Description Probes/Genes FVIII IHC Disease Common endothelial marker, vascular neoplasm, and blast cells in acute megakaryocytic leukemiaCytoplasmic
Factor XIIIa Methodology Immunohistochemistry (IHC) Test Description Probes/Genes FAC 13 IHC Disease Fibrohistiocytic proliferations, dermal dendrocytes, dermatofibroma or benign fibrous histiocytoma (FH),
GATA3 Alternative Name GATA binding protein 3 Methodology Immunohistochemistry (IHC) Test Description Probes/Genes GATA3 IHC Disease Bladder and breast carcinomas, and some types of mesenchymal and
GCDFP-15 Alternative Name Gross Cystic Disease Fluid Protein Methodology Immunohistochemistry (IHC) Test Description Probes/Genes GCDFP IHC Disease Carcinomas of the salivary glands, sweat glands, and
GFAP Alternative Name Glial Fibrillary Acidic Protein Methodology Immunohistochemistry (IHC) Test Description Probes/Genes GFAP IHC Disease Central nervous system (CNS) tumors, and colonic schwannomaIntermediate
Giemsa Alternative Name Wright Giemsa Methodology Special Stains Test Description Probes/Genes GIEMSA SS Disease Staining the blood cells of hematopoietic tissues. It can be applied to all tissues if presence
Glycophorin Methodology Immunohistochemistry (IHC) Test Description Probes/Genes GLYC A IHC Disease Erythroid precursors in bone marrow, AML-M6Glycophorins A and B are major sialoglycoproteins of the human
Glypican Methodology Immunohistochemistry (IHC) Test Description Probes/Genes GLYP3 IHC Disease Distinguish hepatocellular carcinoma from nonmalignant liver lesions and metastasis, Subtyping testicular
GMS (fungus) Alternative Name Grocott Methanamine Silver Methodology Special Stains Test Description Probes/Genes GMS SS Disease Outlines fungal organisms by staining polysaccharides in cell wallsGrocott-Gomori
Granzyme B Methodology Immunohistochemistry (IHC) Test Description Probes/Genes GRANZB IHC Disease T/NK-cell lymphomaEnzyme associated with cytotoxic T lymphocytes; induces apoptosis in target cells of
H. pylori Alternative Name Helicobacter Pylori Methodology Immunohistochemistry (IHC) Test Description Probes/Genes HPYLOR IHC Disease demonstrating Helicobacter pylori infected tissue. Kit may be used
HBME-1 Methodology Immunohistochemistry (IHC) Test Description Probes/Genes HBME1 IHC Disease Thyroid carcinomaThe monoclonal antibody against HBME-1 targets an unknown antigen of mesothelial cells
HepPar 1 Alternative Name Anti-Hepatocyte Specific Antigen Methodology Immunohistochemistry (IHC) Test Description Probes/Genes HEPPAR1 IHC Disease Hepatocellular carcinoma, may be biomarker for early
HHV8 Alternative Name Human Herpesvirus, Type 8 Methodology Immunohistochemistry (IHC) Test Description Probes/Genes HHV8 IHC Disease Kaposi sarcomaHHV8 demonstration by Immunostain
HMB45 Methodology Immunohistochemistry (IHC) Test Description Probes/Genes HMB 45 IHC Disease Melanoma, ruling out diagnosis of perivascular epithelioid cell tumors (angiomyolipoma, lymphangioleiomyomatoisis,
HNF-1-beta Alternative Name Hepatocyte Nuclear Factor 1 Methodology Immunohistochemistry (IHC) Test Description Probes/Genes HNF-1-B IHC Disease Ovarian clear cell carcinoma and endometrial clear cell
HSV I Alternative Name Herpes Simplex 1 Antigen Methodology Immunohistochemistry (IHC) Test Description Probes/Genes HSVI IHC Disease Identification of herpes simplex virus I infectionImmunohistochemistry
HSV II Alternative Name Herpes Simplex 2 Antigen Methodology Immunohistochemistry (IHC) Test Description Probes/Genes HSVII IHC Disease Identification of herpes simplex virus 2 infectionImmunohistochemistry
IgA Alternative Name Immunoglobulin A Methodology Immunohistochemistry (IHC) Test Description Probes/Genes IGA IHC Disease Aiding in the classification of lymphomas and multiple myelomaIgA antibody reacts
With core values rooted in service and integrity, our leadership team sets the bar high.
We consistently strive to set the model for exactly how a reference laboratory should engage with both physicians and patients.
siParadigm is accredited by CLIA (Clinical Laboratory Improvement Amendments) and certified by CAP (College of American Pathologists).
We also hold select state licensure where required.